Thrivent Financial for Lutherans’s Axsome Therapeutics AXSM Stock Holding History

Thrivent Financial for Lutherans’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$305K	Sell	1,246 -319	-20%	-$69.2K	﹤0.01%	2445
2026 Q1	$265K	Sell	1,565 -1	-0.1%	-$173	﹤0.01%	2416
2025 Q4	$233K	Buy	+1,566	New	+$219K	﹤0.01%	2488
2020 Q4	–	Sell	-11,974	Closed	-$853K	–	2466
2020 Q3	$853K	Sell	11,974 -100	-0.8%	-$7.79K	﹤0.01%	1662
2020 Q2	$993K	Hold	12,074	–	–	﹤0.01%	1495
2020 Q1	$710K	Buy	+12,074	New	+$984K	﹤0.01%	1516

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Thrivent Financial for Lutherans's AXSM Position: Q2 2026 in Review

Thrivent Financial for Lutherans reduced its Axsome Therapeutics (AXSM) stake by 20% in Q2 2026, selling an estimated $69.2K and leaving 1,246 shares worth $305K. The position accounts for ﹤0.01% of the portfolio, ranked #2445.

Thrivent Financial for Lutherans first reported a position in AXSM in Q1 2020 and has held it in 6 quarters since. The position peaked at $993K in Q2 2020. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Thrivent Financial for Lutherans held 1,246 shares of Axsome Therapeutics worth $305K as of Q2 2026.
Thrivent Financial for Lutherans sold 319 Axsome Therapeutics shares in Q2 2026, an estimated $69.2K.
Axsome Therapeutics made up ﹤0.01% of Thrivent Financial for Lutherans's portfolio in Q2 2026, its #2445 holding.
Thrivent Financial for Lutherans first reported a position in Axsome Therapeutics in Q1 2020 and has held it in 6 quarters since.
Thrivent Financial for Lutherans's Axsome Therapeutics position peaked at $993K in Q2 2020.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2026, filed 14 Aug 2026.